{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-019864","form_type":"8-K","ticker":"XTNT","cik":"0001453593","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.480244+00:00","generated_at":"2026-06-01T22:53:41.790144+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Xtant Medical Q1 revenue up 55% to $27.9M; raises FY2024 revenue guidance to $116M-$120M","bullets":["Revenue of $27.9M, up 55% YoY from $17.9M.","Net loss of $4.4M ($0.03 per share) vs $2.1M loss in prior year.","Positive Adjusted EBITDA of $0.1M vs -$0.3M a year ago.","Gross margin improved 340 bps to 62.1%.","Full year 2024 revenue guidance raised to $116M-$120M from $112M-$116M."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-019864","json":"https://secwatch.observer/filing/0001493152-24-019864.json","markdown":"https://secwatch.observer/filing/0001493152-24-019864.md","text":"https://secwatch.observer/filing/0001493152-24-019864.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1453593/000149315224019864/0001493152-24-019864-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1453593/000149315224019864/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T22:53:41.790144+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"53af983d1546628058fcf920368bcd4e11e2822c","claim":"Xtant Medical Holdings, Inc. reported first quarter ended March 31, 2024 results: revenue $27.9 million, net income $4.3 million, or $0.03 per share, EPS $0.03 per share. Guidance raised.","evidence_excerpt":"treatment of spinal disorders, today reported financial and operating results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Highlights ● Revenue of $27.9 million, up 55%, compared to the prior year quarter ● Gross margin of 62.1%, up 340 basis points, compared to the prior year quarter ● Net loss of $4.4 million compared to $2.1 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315224019864/0001493152-24-019864-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$27.9 million"},{"label":"Net income","value":"$4.3 million, or $0.03 per share"},{"label":"EPS","value":"$0.03 per share"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"cd3702fd247802c2df5971927ea15c469ebe8c8e","claim":"Xtant Medical Holdings, Inc. reported full year 2024 results: revenue $116 million to $120 million. Guidance raised.","evidence_excerpt":"Xtant Medical raises its expectation for full year 2024 revenue to $116 million to $120 million, up from the Company’s prior guidance of $112 million to $116 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315224019864/0001493152-24-019864-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2024"},{"label":"Revenue","value":"$116 million to $120 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}